# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-266895
Filing Date
2025-11-05
Accepted
2025-11-05 16:07:23
Documents
93
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | d920125d10q.htm iXBRL | 10-Q | 2550924
2 | EX-31.1 | d920125dex311.htm | EX-31.1 | 10374
3 | EX-31.2 | d920125dex312.htm | EX-31.2 | 10359
4 | EX-32 | d920125dex32.htm | EX-32 | 4344
| Complete submission text file | 0001193125-25-266895.txt |  | 13160835

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA | teva-20250930.xsd | EX-101.SCH | 2197826
96 | EXTRACTED XBRL INSTANCE DOCUMENT | d920125d10q_htm.xml | XML | 2671549

Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV Israel
Business Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV Israel 972 (3) 914-8213
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-16174 | Film No.: 251453944
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)